Combatting Substance Abuse Highlights CDER’s 2023 Accomplishments

The historic 2023 approval of OTC naloxone was a highlight of the FDA’s efforts to combat the opioid overdose crisis, according to CDER’s year-end report on drug safety actions.
Source: Drug Industry Daily